1. Home
  2. CLVT vs HROW Comparison

CLVT vs HROW Comparison

Compare CLVT & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clarivate Plc

CLVT

Clarivate Plc

SELL

Current Price

$2.20

Market Cap

1.1B

Sector

Technology

ML Signal

SELL

HROW

Harrow Inc.

SELL

Current Price

$29.43

Market Cap

1.0B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CLVT
HROW
Founded
2016
1998
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
2020
2008

Fundamental Metrics

Financial Performance
Metric
CLVT
HROW
Price
$2.20
$29.43
Analyst Decision
Hold
Strong Buy
Analyst Count
9
9
Target Price
$3.01
★ $62.25
AVG Volume (30 Days)
★ 4.0M
617.3K
Earning Date
11-03-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
68.75
★ 71.43
EPS
★ N/A
N/A
Revenue
★ $974,345,000.00
N/A
Revenue This Year
N/A
$28.13
Revenue Next Year
N/A
$56.02
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 0.61
N/A
52 Week Low
$1.42
$25.76
52 Week High
$3.87
$54.98

Technical Indicators

Market Signals
Indicator
CLVT
HROW
Relative Strength Index (RSI) 60.75 49.41
Support Level $1.83 $28.54
Resistance Level $2.38 $30.28
Average True Range (ATR) 0.19 1.80
MACD 0.02 0.32
Stochastic Oscillator 71.51 42.17

Price Performance

Historical Comparison
CLVT
HROW

About CLVT Clarivate Plc

Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Share on Social Networks: